Sohanya Cheng - Sep 4, 2024 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP & Chief Commercial Officer
Signature
/s/Nancy Smith as Attorney-in-Fact for Sohanya Cheng
Stock symbol
KPTI
Transactions as of
Sep 4, 2024
Transactions value $
-$3,866
Form type
4
Date filed
9/5/2024, 04:13 PM
Previous filing
Mar 4, 2024
Next filing
Nov 1, 2024
SEC
View on sec.gov

Transactions Table

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
F2 Includes 15,898 shares acquired under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2024.